Recent Headlines
Within Biotechnology
NuvOx Receives Notice from the Breakthrough DOD Award for Its Immuno-Oncology Program
On February 11th, 2022, NuvOx Pharma received notice from the Department of Defense (DOD) office of the Congressionally Directed Medical Research Programs (CDMRP) that the Company has been awarded a grant from the Breast Cancer Research Program Breakthrough Award. The grant would fund a... - March 05, 2022 - NuvOx Pharma
Thrivous Introduces Personalized Medicine Coaching
Thrivous, the human enhancement company, has partnered with Consolidated Health Solutions to provide personalized medicine coaching. Thrivous' mission is to help customers access technology with the greatest potential to improve their brains and bodies. Customers may achieve better results when... - March 03, 2022 - Thrivous
Locus Fermentation Solutions Selected for Evolution of Manufacturing Award by Smart Business Magazine
Northeast Ohio startup recognized for its innovative biological manufacturing with a near-zero carbon footprint. - February 27, 2022 - Locus Fermentation Solutions
FOXG1 Research Foundation Hosts Napa Valley Charity Golf Tournament to Accelerate Research for Pediatric Neurological Disorder
Scientists believe FOXG1 may hold the key to unlocking brain disorders affecting millions, including autism, Alzheimer’s, brain tumors and more. - February 23, 2022 - FOXG1 Research Foundation
Timothy Healey Joins the Board of Director at Microvascular Therapeutics
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Timothy Healey to the MVT Board of Directors. Mr. Healey bring a global perspective to pharmaceutical launch and commercialization. “I am very pleased and honored... - February 23, 2022 - Microvascular Therapeutics, Inc.
NuvOx to Participate in the BIO CEO Investor Conference
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in BIO CEO & Investor Conference, held at New York City from February 14 - 17, 2022. The management team will be... - February 11, 2022 - NuvOx Pharma
FOXG1 Research Foundation’s Hourinaz Behesti PhD to Present at BIO CEO & Investor Conference 2022
The FOXG1 Research Foundation, the rare disease patient organization that is driving the science to find treatments for FOXG1 syndrome, will be presenting at the BIO CEO & Conference on February 14 to discuss Tapping into Therapeutic Development for Rare CNS Disorders. Dir. of Science, Hourinaz Behesti will discuss why FOXG1 is a viable target for biotech investment, and the suite of assets that the FRF has developed and characterized to help accelerate drug development. - February 09, 2022 - FOXG1 Research Foundation
ImaRx Investments Receives ISO-7 Certification for Its GMP Manufacturing Suite: Both Microvascular Therapeutics and NuvOx Pharma Will Benefit
ImaRx Investments, LLC, an investment firm based in Tucson, Arizona, has received ISO-7 certification on February 1st for its GMP manufacturing suite. The 1,800 square foot, ISO-5 capable clean room is designed for manufacturing injectable drugs. The facility is the only one of its kind in Southern... - February 08, 2022 - Microvascular Therapeutics, Inc.
Bioplastics International Launches Water Soluble PVA Replacement for Plastics
Bioplastics International creates water soluble PVA products to replace plastics, to stop the plastic pollution of our oceans and beaches. - February 07, 2022 - Bioplastics International
Shiv Kapoor Joins the Board of Directors at Microvascular Therapeutics
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Shiv Kapoor to the MVT Board of Directors. Mr. Kapoor will bring extensive experience in corporate strategy and financing from both biotechnology and finance... - February 03, 2022 - Microvascular Therapeutics, Inc.
MacroArray Diagnostics GmbH (MADx) Partners with ALPCO to Offer a Fully Automated Sample-to-Answer Multiplex Allergy Test Solution to the North American Market
ALPCO (Salem, NH), a leading US producer of novel immunoassay testing platforms, recently announced an exclusive distribution partnership with MacroArray Diagnostics GmbH (Vienna, Austria). Together, they offer a comprehensive line of testing solutions for allergies (IgE-based) and food intolerances (IgG-based), from test material to proprietary hardware and software to process and analyze samples. - February 01, 2022 - ALPCO
Jubilance, Clinically-Proven PMS Relief Supplement, Gets Makeover for 2022
Women's Wellness company Jubilance offers suite of free wellness resources to help women feel their best all month long. Resources include therapist-designed guided meditations for specific PMS symptoms, a PMS research library, curated women's health guides, podcasts, playlists and more. Clinically proven PMS relief supplement Jubilance announces new label makeover for 2022 to better reflect that jubilant feeling of freedom from PMS anxiety, gloominess, stress and irritability. - January 26, 2022 - Jubilance for PMS
NuvOx to Present at Various Bio Forums in JPM Week
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in various Bio forums held Jan 10 – 14, 2022. Dr. Evan Unger, NuvOx’s Chief Executive Officer, is presenting in... - January 14, 2022 - NuvOx Pharma
PharmStars Now Accepting Applications for Spring 2022 Accelerator Program; Startups with Digital Innovations in Neurological Disease Are Welcome to Apply
PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its spring 2022 cohort with the theme, “Digital Innovations in Neurological Disease.” - January 04, 2022 - PharmStars
Global Regenerative Academy Announces Prof. Tahsin Beyzadeoglu as President
Global Regenerative Academy, independent subsidiary of the Global Regenerative Group Inc., has new board leadership. GRA President is now Prof. Tahsin Beyzadeoglu as announced during the opening Ceremony of GRC Dubai 2021 (November 19-21, 2021) by Mr. Mihail Blagoev (GRG Inc. VP) after being elected by the Scientific Board. - December 21, 2021 - Global Regenerative Group
Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round
This Funding will be Used, in Part, to Launch an Asian Phase II/III Randomized Controlled Registration Trial for Advanced Liver Cancer in Q1/2-2022. - December 09, 2021 - Mirror Biologics, Inc.
PharmStars Announces 2021 Accelerator Graduates
12 digital health startups have successfully completed PharmStars’ inaugural 10-week pharma-focused accelerator program. - December 08, 2021 - PharmStars
Doubling Down: HCPA Panel Selects Locus Performance Ingredients for Two Innovation Awards at XPAND2021
Green Tech Start-Up Recognized for Advancing Sustainable Cleaning Products with High-Performance Biosurfactant Ingredients and Carbon-Neutral Production Process. - December 08, 2021 - Locus Performance Ingredients
Pelvic Floor HIFEM (Emsella) Improves the Intensity and Duration of Male Orgasm
Dr. Judson Brandeis studied the Emsella, a device that has been FDA-approved for the treatment of urinary incontinence by stimulating the pelvic floor muscles, in mid-life men with weak or delayed ejaculation. He discovered that four weekly thirty-minute treatments with the Emsella protocol 2 was enough to improve the self-reported intensity and duration of ejaculation. - November 30, 2021 - BrandeisMD
Parvus Therapeutics Announces Development and Manufacturing Agreement with Resilience to Advance Novel Autoimmune Drug Candidate PVT201
Parvus Therapeutics, a biopharmaceutical company developing Navacim™ platform-based disease-specific immunoregulator therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function,... - November 29, 2021 - Parvus Therapeutics U.S., Inc.
LPA Statement Regarding Voxzogo™
Little People of America (LPA), the world’s oldest and largest support organization for people with dwarfism and their families, has been tracking biotechnical developments for the treatment of individuals with Achondroplasia. LPA President, Mark Povinelli, says, "With the FDA approval... - November 21, 2021 - Little People of America Inc.
Parvus Therapeutics and Ardena Enter Agreement for Tech Transfer, Scale-Up and GMP Manufacturing of Navacim Nanoparticles
Today Parvus announced it has entered into an agreement with Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO), for process development, scale-up and GMP manufacturing of NavacimTM nanoparticles, a key building block for all of our Navacim platform drug development candidates. - November 19, 2021 - Parvus Therapeutics U.S., Inc.
CANNA/Hemp Extraction Labs USA Announces Joint Venture Partnerships for Cannabis Cultivators/Growers and Cannapreneurs
CANNA/Hemp Extraction Labs USA (CHELUSA) announced today they are offering to finance and commission Cannabis Extraction Labs and Cannabis Cloning Labs in NM, NJ, AZ, IL, MT and VA. CHELUSA is looking to form strategic partnerships with Cultivators/Growers and Cannapreneurs in these key states. The... - November 18, 2021 - Hemp Extraction Labs USA
PharmStars Announces Showcase Event for Inaugural Class
PharmStars, a pharma-focused accelerator for digital health startups, announces the start of its 2021 Showcase Event. At the Showcase Event, the 12 startups in the accelerator’s current cohort will pitch their digital health solutions to PharmStars’ pharma members. The startups and pharma members will also have the opportunity to meet privately to discuss potential partnership opportunities. - November 17, 2021 - PharmStars
Mirror Biologics Announces Issuance of US Patent Covering Next Generation Therapeutic Vaccine Technology for Treatment of Cancer and Infectious Disease
Mirror Biologics, Inc., a private clinical stage biopharmaceutical company, today announces the issuance of US Patent No. 11,160,852, “Method of Vaccinating Using Allogeneic Cells,” covering methods for creating a next generation of therapeutic vaccines against cancers and infectious... - November 17, 2021 - Mirror Biologics, Inc.
PharmStars Welcomes Sumitovant Biopharma as Its Newest Member
PharmStars, the only pharma-focused, member-based accelerator for digital health startups, is pleased to announce that Sumitovant Biopharma has become its newest pharma member, joining existing members including Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk. PharmStars focuses on bridging the "pharma-startup gap." PharmStars provides startups with education and mentoring to help them engage with pharma as clients and partners. - November 03, 2021 - PharmStars
Cord for Life®, Inc. Announces Cord Blood Clinical Trial Phase I Trial for the Treatment of Lower Back Pain of the Sacroiliac Joint
Cord for Life®, a full-service cord blood bank with over 25 years of experience, today announced plans to conduct a clinical trial to treat lower back pain arising from the Sacroiliac Joint (SIJ) using a biological therapeutic derived from umbilical cord blood. The company has received FDA... - October 29, 2021 - Cord For Life
Pascal Biosciences Announces Financing
Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV: PAS) (OTC: PSCBF) (FSE: 6PB-FF) is pleased to announce a non-brokered private placement financing of up to 9,000,000 units (each a “Unit”) of securities at a price of $0.10 per Unit for aggregate gross proceeds of up to $900,000.00 (the “Offering”). - October 29, 2021 - Pascal Biosciences
OmeCare and Hillsborough City School District Renew Partnership for Student and Faculty COVID-19 PCR Testing
Partnership helps district ensure safety standards and meet COVID-19 testing protocols for the 2021-2022 school year. - October 16, 2021 - OmeCare
NuvOx Pharma Receives Phase I STTR Grant from NINDS for Preclinical Studies in Stroke
NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small Business Technology Transfer (STTR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) under award number R41NS124450. STTR programs are highly competitive programs that... - October 12, 2021 - NuvOx Pharma
Omni-HC Selected to Participate in “Audience Amplification” Workshop at Prestigious Global Medical Affairs Meeting
Omni Healthcare Communications has been selected by the Medical Affairs Professional Society to convene a workshop on scientific communication amplification at the MAPS 2022 Global Annual Meeting. - October 02, 2021 - Sunny Ayr Holdings
OmeCare and LifeSite Announce COVID-19 Testing Solution Partnership
The partnership provides a turnkey approach for workplaces, schools, major conventions and other group events looking to ensure safety and meet governmental mandates for students, staff, employees and event participants. - October 01, 2021 - OmeCare
Cayman Chemical Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration
The National Institute of Dental and Craniofacial Research has awarded Cayman Chemical with a $1,700,500 grant to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage... - September 19, 2021 - Cayman Chemical Company
AdvantaPure(R) Announces Fall Trade Show Appearances - Includes Events in the Northeast U.S.
AdvantaPure, the high purity division of NewAge Industries, will exhibit its silicone and TPE tubing and molded assemblies at the ISPE Boston Show, BioProcess International 2021, and Interphex, all taking place in September and October. AdvantaPure will also highlight its recent clean room expansion and its in-process building renovation at the events. The company is increasing its tubing manufacturing capacity to help meet demand for its Single-Use products. - September 16, 2021 - AdvantaPure
Clean-Label Micellar Water Formulation Banishes Trace Chemicals and Outperforms Leading Brand
Locus Performance Ingredients and Genomatica introduce sustainable, natural cleanser featuring Ferma® S sophorolipids and Brontide® natural butylene glycol that eliminates chemical additives and outperforms the current leading brand. The next-generation micellar water replaces controversial legacy ingredients with plant-derived ingredients that provide all the traditional micellar water benefits, but with superior functionality and sustainability. - September 11, 2021 - Locus Performance Ingredients
Mirror Biologics, Inc. Announces Initial Clearance for Phase II/III Clinical Trial (ALIVE) in Advanced Liver Cancer
Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccine immunotherapy for cancer and infectious diseases where... - September 10, 2021 - Mirror Biologics, Inc.
Globally Recognized Agricultural Leader to Become First N.C. PSI Director
Adrian Percy, one of the world’s top leaders in the agriculture field, is set to become the first executive director of the North Carolina Plant Sciences Initiative (N.C. PSI): a world-class research and innovation effort that is poised to solve some of the world’s grandest agricultural... - September 09, 2021 - North Carolina Plant Sciences Initiative
Locus Performance Ingredients Launches New Biosurfactant-Based Personal Care Formulations to Ease Adoption of Clean Label Trend
Ready-to-use formulations utilizing novel Ferma® S sophorolipids help CPG companies replace commonly used surfactants, boost product performance and maximize sustainability. - September 09, 2021 - Locus Performance Ingredients
NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts the Efficacy of Immunotherapy in a Mouse Model of Triple Negative Breast Cancer
NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the efficacy of immunotherapy in a mouse model of triple negative breast cancer. Triple negative breast cancer (TNBC) is a particularly deadly form of... - September 09, 2021 - NuvOx Pharma
Scientists at AbboMax, Inc. Developed the New Panels of Monoclonal Antibodies to Study B- and T-Cell Lymphomas
Lymphoma is a malignant transformation of either B or T cells or their subtypes. All lymphoma subtypes combined are the seventh most common cancer in the United States. The B-cell lymphomas are types of lymphoma affecting B cells. About 85% of lymphomas are of B-cell origin. T-cell lymphomas are lymphomas that affect T cells. AbboMax has developed the new panels of monoclonal antibodies to study B- and T-cell lymphomas. - September 03, 2021 - AbboMax, Inc.
Defined Bioscience Licenses FGF2-STAB (G3) for Use in Stem Cell Media
Defined recently concluded a licensing agreement with Czech Republic-based Enantis for global use of Enantis’ patented FGF2-STAB® technology both alone and in stem cell media formulations. FGF2-STAB®, originally coined FGF2-G3, was developed by Enantis and Masaryk University, using... - August 30, 2021 - Defined Bioscience Inc.
Locus Performance Ingredients Forms Industry-Leading Advisory Board to Accelerate Global Use of Biosurfactant Innovations
The panel of top CPG and entrepreneurial executives will drive adoption of sustainable biosurfactant ingredients in product formulations. - August 26, 2021 - Locus Performance Ingredients
Omni Healthcare Communications & Res Consortium Form Alliance to Expand Medical Affairs Capabilities
Omni Healthcare Communications (Omni-HC), a US based medical communications firm delivering solutions for today’s scientific exchange challenges, is pleased to announce the formation of a strategic alliance with Res Consortium (Res) of the United Kingdom, a cross-sector leader in digital... - August 21, 2021 - Sunny Ayr Holdings
Reverie Psychedelics and Indiana Health Group Partner to Develop World-Class Psychedelic Research Center
Reverie Psychedelics (Reverie), a leading and rapidly growing psychedelic – assisted psychotherapy clinic and research organization, has further expanded its footprint and capabilities by partnering with Indiana Health Group (IHG), the largest provider of psychiatric and mental health and... - August 05, 2021 - Reverie Psychedelics
Foxx Life Sciences Celebrates Major Expansion
Foxx Life Sciences celebrates two new manufacturing facilities in Londonderry, New Hampshire and Hyderabad, India. The new locations add four additional SUT (Single Use Technologies) Cleanrooms that will allow Foxx to meet the high demands of their biotechnology and biopharmaceutical customers. New... - August 04, 2021 - Foxx Life Sciences
NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM in Ischemic Stroke
NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke. Stroke affects nearly 800,000 patients each year in the US. It is the fourth leading cause of death in this... - July 29, 2021 - NuvOx Pharma
NuvOx Pharma Announces Issuance of New Patent Covering a New Method of Treating Cancer Utilizing Lead Drug Candidate NanO2TM
NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has further expanded its patent portfolio in oxygen therapeutics with the issuance of US Patent No. 10946097, “Fractionated radiotherapy and chemotherapy with an oxygen therapeutic,” describing... - July 23, 2021 - NuvOx Pharma
Microvascular Therapeutics Has Received Funds from the National Heart, Lung and Blood Institute (NHLBI)
Microvascular Therapeutics (MVT) has received funds from the from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health for its program to treat cardiovascular disease, which kills more Americans than any other disease. As a leader in fluorocarbon... - July 19, 2021 - Microvascular Therapeutics, Inc.
Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase I/II Universal Viral Vaccine Clinical Trial (ALLOPRIME) in Healthy Adults Over 65 Years Old
Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccines for cancer and infectious diseases where the active... - July 14, 2021 - Mirror Biologics, Inc.
Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer
Mirror Biologics, Inc. (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ cancer vaccines in which the active ingredients are living... - July 09, 2021 - Mirror Biologics, Inc.